Jupiter Neurosciences (JUNS) began trading on the Nasdaq on Tue 3 Dec 24

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform products primarily for the treatment of neuroinflammation. It is developing JNS101, which is in Phase II trial for the treatment of Friedreich's Ataxia, a rare inherited disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS108 that is in Phase II trial for treating mild cognitive impairment/early Alzheimer's disease. 

The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021.

• Sector: Healthcare
• Industry: Biotechnology
• Full Time Employees: 4
• Incorporated in 2015 
• Headquartered in Jupiter, Florida
• https://jupiterneurosciences.com/

Ticker: JUNS

 

One and two weeks later:

Aspen Aerogels (ASPN) : 10-year performance

• Aspen originally filed for an IPO on June 24, 2011 with the intent of raising $115M on the NASDAQ exchange, later retracted the filing, possibly due to an unfortunate coincident global downturn in construction.

Aspen Aerogels, Inc. designs, develops, manufactures, and sells aerogel insulation products primarily for use in the energy infrastructure and sustainable insulation materials markets.

The company offers PyroThin thermal barriers for use in lithium-ion batteries in electric vehicles and energy storage industries; Pyrogel XTE that reduces the risk of corrosion under insulation in energy infrastructure operating systems; and Pyrogel HPS for applications within the power generation market.

The company was founded in 2001 and is headquartered in Northborough, Massachusetts.

ServiceTitan (TTAN) began trading on the Nasdaq on Thur 12 Dec 24

ServiceTitan is an American cloud-based software company headquartered in Glendale, California. It provides customer relationship management software for tradespersons, with applications focused on sales, customer service, marketing automation, e-commerce and analytics.

• Founded: 2012
• Employees: 2,870
• Website: servicetitan.com

ServiceTitan targets businesses in plumbing, landscaping, electrical and other trades, with software for managing sales leads, recording calls, generating quotes and scheduling jobs. As of Jan. 31, it had about 8,000 customers with more than $10,000 in annualized billings.

Ara Mahdessian, CEO and co-founder of ServiceTitan, and Vahe Kuzoyan, president and co-founder of ServiceTitan, attend the company’s IPO at the Nasdaq Market in New York City, U.S., December 12, 2024.  / Brendan Mcdermid | Reuters

ServiceTitan’s IPO is notable because few tech companies have taken the leap into the public market since late 2021, when rising interest rates and soaring inflation pushed investors out of risky assets. ServiceTitan is the first significant venture-backed tech company to go public since Rubrik’s (RBRK) debut in April. A month before that, Reddit (RDDT) started trading on the New York Stock Exchange.

 

BioAge Labs (BIOA) stops Eli Lilly-collaborated obesity trial on safety concerns

• Tirzepatide is an active ingredient of Eli Lilly’s popular Zepbound and Mounjaro.
• The trial was designed to evaluate the efficacy as measured by body weight reduction and other outcomes, safety, and tolerability of two oral doses of azelaprag (300 mg, once or twice daily) in combination with tirzepatide (5 mg subcutaneous injection once weekly).
• In parallel to evaluating azelaprag, Company will continue to advance earlier platform-derived programs, including IND submission for CNS penetrant NLRP3 inhibitor anticipated in the second half of 2025.

 

On Friday, BioAge Labs Inc. (NASDAQ:BIOA) announced that it will discontinue the ongoing STRIDES Phase 2 study of its investigational drug candidate, azelaprag.

STRIDES was being conducted in collaboration with Eli Lilly And Co’s (NYSE:LLY) Chorus clinical development organization. Top-line results were anticipated in the third quarter of 2025.

The move follows after liver transaminitis without clinically significant symptoms was observed in some subjects receiving azelaprag.

STRIDES is a Phase 2 clinical trial of azelaprag as monotherapy and in combination with tirzepatide that planned to enroll approximately 220 individuals with obesity aged 55 years and older.

Tirzepatide is an active ingredient of Eli Lilly’s popular Zepbound and Mounjaro.

The trial was designed to evaluate the efficacy as measured by body weight reduction and other outcomes, safety, and tolerability of two oral doses of azelaprag (300 mg, once or twice daily) in combination with tirzepatide (5 mg subcutaneous injection once weekly).

An azelaprag monotherapy arm was included to provide additional safety information.

The company said no transaminase elevations were observed in the tirzepatide only treatment group.

Of 204 subjects enrolled in STRIDES, 11 subjects in the azelaprag treatment groups were observed to have transaminase (liver enzymes) elevations with no clinically significant symptoms. Dosing of all subjects will be discontinued, and no additional subjects will be enrolled.

Clinical follow-up of enrolled subjects will continue off-drug. The company intends to further analyze available STRIDES clinical data from all enrolled subjects and share updated plans for azelaprag in the first quarter of 2025.

The company’s brain-penetrant NLRP3 inhibitors are progressing toward IND submission, anticipated in the second half of 2025. The NLRP3 inhibitor program targets neuroinflammation linked to metabolic and neurodegenerative diseases.

As of September 30, BioAge had approximately $334.5 million in cash and cash equivalents, which is expected to be sufficient to fund operations and capital expenses into 2029.

In October, BioAge Labs closed its upsized initial public offering of 12.65 million shares at $18 per share.

Xilio Therapeutics (XLO) : 3-year performance

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. 

• Sector: Healthcare
• Industry: Biotechnology
• Full Time Employees: 73
• Founded in 2016 
• Headquartered in Waltham, Massachusetts
• https://xiliotx.com

Ticker: XLO

October 22, 2021 : initial public offering of 7,353,000 shares of its common stock at a price to the public of $16.00 per share. 

 

 

 

Pulse Biosciences (PLSE) : 8-year performance

Pulse Biosciences CEO Burke T. Barrett to resign, effective today; also to resign from Board

• The Company's Chief Commercial Officer, Kevin P. Danahy, and its Chief Technology Officer, Darrin R. Uecker, will serve as the Company's principal executive and principal financial officers until such time as the Company has identified a chief executive officer to replace Mr. Barrett.
• Messrs. Danahy and Uecker have both served as the Company's Chief Executive Officer at different times before Mr. Barrett.

3 days later

Software startup ServiceTitan seeks up to $5.2 billion valuation in US IPO

 (Reuters) -Software startup ServiceTitan is seeking a valuation of up to $5.16 billion in its U.S. initial public offering, it said on Tuesday, in what could be one of the final few flotations of the year that saw a revival in the market for new listings.

• https://www.servicetitan.com/

Glendale, California-based ServiceTitan is looking to raise up to $502 million by offering 8.8 million shares priced between $52 and $57 each.

ServiceTitan will join a handful of venture capital-backed firms, including social media platform Reddit and cybersecurity software firm Rubrik, which have all gone public this year.

ServiceTitan - whose rivals include software vendors Salesforce, SAP, and Jobber - was incorporated in 2007 as LinxLogic. It first launched its platform in 2012 and was renamed to ServiceTitan in 2014.

While it fetched a $9.5 billion valuation during the 2021 fundraising boom, ServiceTitan was valued at $7.6 billion after a 2022 funding round, PitchBook data showed.

ServiceTitan will be listed on the Nasdaq under the symbol "TTAN."

IPOs this week : Nov 25 - 29, 24 (wk 48)

Pony AI – Guangzhou, China, million shares, priced at $11-$13, managed by Goldman (Asia) BofA. Proposed Nasdaq symbol PONY. Business: China-based developer of autonomous vehicle systems for robotaxis and robotrucks.

Brazil Potash – Toronto, 4.3 million shares, priced at $15-$18, managed by Cantor Fitz. Bradesco. Proposed NYSE symbol GRO. Business: Developing a potash mining project in Brazil’s Amazon basin.

BrilliA – Singapore, 2.5 million shares, priced at $4-$5, managed by A.G.P.. Proposed NYSE American symbol BRIA. Business: Provider of women’s lingerie and intimate apparel.

Venu Holding – Colorado Springs, Colo., 1 million shares, priced at $10, managed by ThinkEquity. Proposed NYSE American symbol VENU. Business: Owns and operates music venues and restaurants.

Jinxin Technology – Shanghai, 1.9 million shares, priced at $4-$5, managed by Craft Capital WestPark Capital. Proposed Nasdaq symbol NAMI. Business: Provides a digital textbook and educational content platform for K-9 students in China.

New Century Logistics – Hong Kong, 1.3 million shares, priced at $4-$5, managed by Craft Capital R. F. Lafferty. Proposed Nasdaq symbol NCEW. Business: Hong Kong-based provider of air and ocean freight forwarding services.

Creative Global Tech – Hong Kong, 1.3 million shares, priced at $4-$5, managed by Benjamin Securities. Proposed Nasdaq symbol CGTL. Business: Hong Kong-based seller of pre-owned consumer electronics.

IPOs this week : Nov 18 - 22, 24 (wk 47)

Pony AI – Guangzhou, China, 15 million shares, priced at $11-$13, managed by Goldman (Asia) BofA. Proposed Nasdaq symbol PONY. Business: China-based developer of autonomous vehicle systems for robotaxis and robotrucks.

Brazil Potash – Toronto, 4.3 million shares, priced at $15-$18, managed by Cantor Fitz. Bradesco. Proposed NYSE symbol GRO. Business: Developing a potash mining project in Brazil’s Amazon basin.

Venu Holding – Colorado Springs, Colo., 1 million shares, priced at $10, managed by ThinkEquity. Proposed NYSE American symbol VENU. Business: Owns and operates music venues and restaurants.

Jinxin Technology – Shanghai, 1.9 million shares, priced at $4-$5, managed by Craft Capital WestPark Capital. Proposed Nasdaq symbol NAMI. Business: Provides a digital textbook and educational content platform for K-9 students in China.

vTv Therapeutics (VTVT) : 9-year performance

vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer. It offers Azeliragon, TTP399, TTP273, HPP593, HPP737, and the Nrf2/Bach1 program.

• Founded: 2015
• Headquarters: High Point, North Carolina
• Employees: 16
• vtvtherapeutics.com

 

 

 

 

 

Chinese self-driving firm Pony AI seeks up to $4.5 bln valuation in US IPO

Pony AI is seeking a valuation of up to $4.48 billion in its U.S. initial public offering, it said on Thursday, as the Chinese self-driving firm moves ahead with its long-sought plan for a New York listing.

• https://www.pony.ai/
  

Pony, founded in 2016 and backed by Japanese automaker Toyota (TM), opens new tab, aims to raise up to $195 million by offering 15 million American Depositary Shares priced between $11 and $13 each.
 

Self-driving firms are looking to raise capital as they seek to scale operations. Guangzhou-based Pony, whose fleet includes over 250 robotaxis and 190 robotrucks, will enter the U.S. stock market on the heels of rival WeRide's (WRD) Nasdaq debut in October.

 

 

By S5A-0043 - (CHN-Guangdong) Pony.ai Lexus RX450h P6001 2024-05-24, CC BY 2.0

 

===ZenaTech (ZENA) began trading on the Nasdaq on Tue 1 Oct 24

Founded: 2017

Headquarters: Toronto, Ontario, Canada

Website: zenatech.com

Employees: 11

Oct2: ZenaTech announced that its subsidiary company, ZenaDrone, has been granted an exemption by the Federal Aviation Authority for visual line-of-sight commercial applications and data collection in the United States, subject to specified conditions and limitations

• This approval enables live testing and evaluation of the ZenaDrone 1000 product with US-based partners and potential customers, and live demonstration of the product's capabilities may commence at US drone tradeshow and exhibit events.
• The ZenaDrone 1000 is an autonomous drone product designed for stable flight, maneuverability, heavy lift capabilities, incorporating innovative software technology, AI, sensors, and purpose-built attachments, along with compact and rugged hardware engineered for industrial use. Currently, it is in use by farmers in Ireland enabling smart farming, plant tracking, and crop management, and it has been piloted in the field with the US military for delivery of temperature-controlled critical medical supplies.

ZenaTech announced that it will pursue a series of acquisitions to launch its Drone-as-a-Service (DaaS) operations. These acquisitions have the potential to dramatically increase company revenue and will underpin its Drone-as-a-Service (DaaS) business by integrating ZenaDrone's drone technology into the target company operations.

Opendoor Technologies (OPEN) : 4-year performance

Founded in 2014, Opendoor operates as a tech-driven platform that buys homes, makes minor repairs and quickly resells them, charging sellers a commission — typically 1% higher than the market rate — for the speed and convenience of the process. 

Buyers can view homes via a smartphone app, with or without an agent, and agents still receive the standard commission if involved. Sellers, meanwhile, can receive a cash offer within days by filling out an online questionnaire and uploading photos, bypassing the need for staging or open houses. 

Home prices are set using algorithms, further streamlining the transaction process.

 

Zeta Global (ZETA) : 4-year performance

Zeta Global Holdings Corp. is an American marketing technology company which offers companies a suite of multichannel marketing tools focused on creating, maintaining, and monetizing customer relationships.

• Sector(s): Technology
• Industry: Software - Infrastructure
• Founded in 2007
• Headquartered in New York, New York
• Full Time Employees: 1,783
• https://www.zetaglobal.com

Ecovyst (ECVT) reported earnings on Thur 31 Oct 24 (b/o)

The company was formerly known as PQ Group Holdings Inc. and changed its name to Ecovyst Inc. in August 2021.

• Sector(s): Basic Materials
• Industry: Specialty Chemicals
• Full Time Employees: 911
• Founded in 1831 
• Headquartered in Malvern, Pennsylvania
• https://www.ecovyst.com

** charts 1 day after earnings **

Iterum Therapeutics (ITRM) : 6-year performance

• Sector(s): HealthcareIndustry: Biotechnology
• Full Time Employees: 14
• Incorporated in 2015 
• Headquartered in Dublin, Ireland
• https://www.iterumtx.com

 

 

 

 

Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum Therapeutics is advancing the development of its first compound, sulopenem, a novel penem anti-infective compound, with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum Therapeutics has submitted an NDA for oral sulopenem for the treatment of uncomplicated urinary tract infections in adult women, which has been accepted for review by the U.S. Food and Drug Administration and has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications. For more information, please visit http://www.iterumtx.com.

Day One (DAWN) reported earnings on Wed 30 Oct 24 (a/h)

ticker: DAWN

** charts after earnings **

 

 

BRISBANE, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced its third quarter 2024 financial results and highlighted recent corporate achievements.

Achieved $20.1 million in OJEMDATM (tovorafenib) net product revenue.

Ended the third quarter with $558.4 million in cash, cash equivalents and short-term investments.

Program Highlights

• Strong growth in OJEMDA net revenue with $20.1M in the third quarter of 2024, representing a 145% increase over the second quarter of 2024.
• Quarterly prescriptions (TRx) grew to 619 in the third quarter of 2024, representing a 159% increase over the second quarter of 2024.
• Day One expects to dose the first patient in the Phase 1a portion of the Phase 1a/b clinical trial of DAY301 by the end of 2024 or in the first quarter of 2025.
• Day One provided updated duration of response data from the registrational Phase 2 FIREFLY-1 trial investigating tovorafenib in patients with BRAF-altered, relapsed or progressive pLGG. For the 77 patients enrolled on Arm 1, which was the dataset used to assess OJEMDA’s efficacy, the median duration of response is 18 months.
• The pivotal Phase 3 FIREFLY-2/LOGGIC clinical trial evaluating tovorafenib as a front-line therapy in patients aged 6 months to 25 years with pLGG continues to enroll patients in the United States, Canada, Europe, Australia and Asia, with more than 100 sites activated.

Corporate Highlights and Upcoming Milestones

• Day One and Ipsen entered into an exclusive licensing agreement to commercialize tovorafenib outside of the U.S. in July 2024. Under the agreement, Day One received approximately $111 million upfront in cash and equity investment at a premium with up to approximately $350 million in additional launch and sales milestone payments as well as tiered double-digit royalties starting at mid-teens percentage on net sales.
• Day One entered into a definitive agreement for an oversubscribed private placement of its securities for total gross proceeds of approximately $175 million in July 2024.

IPOs this week : Oct 28 - Nov 1, 24 (wk 44)

 

Brazil Potash – Toronto, 4.3 million shares, priced at $15-$18, managed by Cantor Fitz. Bradesco. Proposed NYSE symbol GRO. Business: Developing a potash mining project in Brazil’s Amazon basin.

Peak Resources LP – Durango, Colo., 4.7 million shares, priced at $13-$15, managed by Janney Roth Cap.. Proposed NYSE American symbol PRB. Business: US oil and natural gas producer operating in the Powder Ridge Basin.

Cuprina Holdings – Singapore, 3.8 million shares, priced at $4-$4.50, managed by Network 1. Proposed Nasdaq symbol CUPR. Business: Singapore-based provider of skincare and chronic wound care products.

Jupiter Neurosciences – Jupiter, Fla., 2.8 million shares, priced at $4-$5, managed by Dominari Sec. Revere Sec.. Proposed Nasdaq symbol JUNS. Business: Phase 1 biotech developing an oral therapy for neuro-inflammation.

Diginex – Hong Kong, 2.3 million shares, priced at $4-$6, managed by Dominari Sec. Revere Sec.. Proposed Nasdaq symbol DGNX. Business: Provides software that enables businesses to collect, analyze, and report ESG data.

FBS Global – Singapore, 2.3 million shares, priced at $4.50-$5, managed by WallachBeth. Proposed Nasdaq symbol FBGL. Business: Provides interior design and fit-out services in Singapore.

Jinxin Technology – Shanghai, 1.9 million shares, priced at $4-$5, managed by Craft Capital WestPark Capital. Proposed Nasdaq symbol NAMI. Business: Provides a digital textbook and educational content platform for K-9 students in China.

Libera Gaming Operations – Tokyo, 1.3 million shares, priced at $4-$6, managed by Craft Capital Boustead. Proposed NYSE American symbol LBRJ. Business: Operates pachinko gaming halls in Japan.

Septerna (SEPN) began trading on the Nasdaq on Fri 25 Oct 24

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. 

Septerna was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021.

• Sector(s): Healthcare
• Industry: Biotechnology
• Full Time Employees: 68
• Incorporated in 2019 
• Headquartered in South San Francisco, California
• https://septerna.com

Septerna opened at $23.50 after pricing 16.0 mln share IPO at $18/share, above the $15-17 expected range

Septerna, a clinical-stage pharmaceutical company with an initial focus on rare endocrine diseases, draws strong interest for its IPO

• After pricing its upsized 16.0 mln share IPO at $18, above the $15-$17 expected price range, Septerna (SEPN) opened for trading at $23.50, good for a 31% opening gain. 
• The company has developed a proprietary "Native Complex Platform" that it believes will usher in a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery. GPCRs are a family of cell membrane receptors that regulate physiological processes in nearly every organ system in the human body.
• Its lead product candidate is SEP-876, which is currently in Phase 1 studies and being evaluated for the treatment of Hypoparathyroidism -- a rare endocrine disease characterized by insufficient levels of parathyroid hormone that affects approximately 70,000 patients in the United States. The company expects to report data on the trial in mid-2025.
• Including the proceeds from this offering, SEPN has approximately $400.0 mln in cash and cash equivalents. SEPN believes that it will have enough capital to fund its operations and clinical trials into 2H27.

Vroom (VRM) : 4-year performance

Vroom, Inc. is a parent company of United Auto Credit Corporation and CarStory. Previously, it was a used car retailer and e-commerce company that let consumers buy, sell, and finance cars online. Vroom ceased e-commerce automotive sales operations on January 22, 2024.

• Ticker: VRM

WeRide (WRD) began trading on the Nasdaq on Fri 25 Oct 24

WeRide is the world’s first publicly listed universal autonomous driving technology company and the first publicly listed Robotaxi company.

• Sector(s): Consumer Cyclical
• Industry: Auto Manufacturers
• Full Time Employees: 2,227
• incorporated in 2017 
• Headquartered in Guangzhou, China
• https://www.weride.ai